GeneCentric
Durham, US · Founded 2011 · 14 employees on LinkedIn · 2 known investors
Find your way into GeneCentric
748 people in our graph share verified history with the GeneCentric team — schools, employers, funds. One of them is your warm intro.
Glen Andersonunlockedknows MICHAEL MILBURN · together at University of Michigan (overlapped)
knows the team · via University of Michigan
×5knows the team · via University of California, Berkeley
knows the team · via Harvard Medical School
knows the team · via University of North Carolina at Chapel Hill
×3knows the team · via Stanford University School of Medicine
A biotech company offering gene expression analysis tools for blood-based biomarker detection across multiple cancer types. The company develops molecular signatures and liquid biopsy solutions for biopharma, diagnostics, and CRO partners.
Founders & leadership
GeneCentric was founded in 2011 by Charles M. Perou.
CM
Charles M. PerouinFounder and DirectorCharles M. Perou holds a PhD in Experimental Pathology from the University of Utah and conducted postdoctoral research with David Botstein at Stanford University. He has spent over two decades studying cancer genomics and molecular subtypes, particularly in breast cancer research, and co-founded GeneCentric Therapeutics to develop genomic assays and molecular signatures for personalized cancer diagnostics.
MM
MICHAEL MILBURNinCEO and PresidentMichael Milburn is an executive and scientist with over 20 years in biotechnology leadership at companies including Plexxikon, Sirtris Pharmaceuticals, Metabolon, and GeneCentric Therapeutics, with published research in drug design, computational biology, metabolomics, and genomics.
DN
David Neil HayesNamed on SEC filing
Board
CT
ML
AL
Arnold LevineBoard director
PR
Prasanth ReddyBoard director
DH
Don HardisonBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$21.3M disclosed across 6 rounds · 2013–2025
▶$2MraisedJun 2025 · 9 investors · BiotechnologyRule 506(b)
▶$2MraisedJun 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CLAY THORPDirector
- MICHAEL MILBURNExecutive Officer, Director
- ARNOLD LEVINEDirector
- CHARLES PEROUDirector
- Prasanth ReddyDirector
- MYLA LAI-GOLDMANDirector
- Don HardisonDirector
- Offering amount
- $5M
- Amount sold
- $2M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedSep 2022 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedSep 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ARNOLD LEVINEDirector
- CLAY THORPDirector
- CHARLES PEROUDirector
- MYLA LAI-GOLDMANDirector
- ELLEN LUBMANDirector
- MICHAEL MILBURNExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $2.5M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedOct 2021 · 1 investors · BiotechnologyRule 506(b)
▶$4.5MraisedOct 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ellen LubmanDirector
- Michael V. MilburnExecutive Officer, Director
- Perou CharlesExecutive Officer, Director
- Clay ThorpDirector
- Myla Lai-GoldmanExecutive Officer, Director
- Arnold LevineDirector
- Offering amount
- $7.5M
- Amount sold
- $4.5M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedJan 2021 · 4 investors · BiotechnologyRule 506(b)
▶$1.2MraisedJan 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles PerouExecutive Officer, Director
- Arnold LevineDirector
- Clay ThorpDirector
- Michael MilburnExecutive Officer, Director
- Myla Lai-GoldmanExecutive Officer, Director
- Ellen LubmanDirector
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.1MraisedJan 2017 · 4 investors · BiotechnologyRule 506(b)
▶$6.1MraisedJan 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Myla Lai-GoldmanExecutive Officer, Director
- Clay ThorpDirector
- Arnold LevineDirector
- David Neil HayesExecutive Officer, Director
- Charles PerouDirector
- Offering amount
- $8.6M
- Amount sold
- $6.1M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedJul 2014 · 4 investors · BiotechnologyRule 506(b)
▶$5MraisedJul 2014 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles PerouDirector
- Myla Lai-GoldmanExecutive Officer, Director
- Arnold LevineDirector
- David Neil HayesExecutive Officer, Director
- Clay ThorpDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Jun 2013
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapThumbnail for Seragon Pharmaceuticals10 shared keywordsGenentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
Labcorp8 shared keywordsLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
Companies competing with GeneCentric for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does GeneCentric do?
- A biotech company offering gene expression analysis tools for blood-based biomarker detection across multiple cancer types. The company develops molecular signatures and liquid biopsy solutions for biopharma, diagnostics, and CRO partners.
- Who founded GeneCentric?
- GeneCentric was founded by Charles M. Perou in 2011.
- Who are GeneCentric's investors?
- GeneCentric's investors include Hatteras Venture Partners, IAG Capital Partners.
- How much funding has GeneCentric raised?
- GeneCentric has disclosed $21.3M raised across 6 rounds.
- Where is GeneCentric headquartered?
- GeneCentric is headquartered in Durham, US.